Fluid Biomed Inc.

Fluid Biomed Inc. , based in Calgary, Canada, specializes in innovative medical devices, particularly a pioneering polymer-based brain stent designed for treating aneurysms. Founded in 2012, Fluid Biomed Inc. focuses on developing advanced medical devices.

The company has not undergone any significant business pivots or changes in operations. Fluid Biomed is headquartered in Calgary, Canada, and was co-founded by Alim Mitha and John Wong, who also serves as the CEO. The company has successfully raised CAD 38. 42 million in its Series A funding round that took place on December 16, 2024, with participation from investors including Amplitude, IAG Capital Partners, LifeArc, METIS Innovative, and ShangBay Capital.

Fluid Biomed's primary product offering is a polymer-based brain stent engineered to treat aneurysms, affecting up to 5% of the global population. This stent combines polymer and metal to provide a scaffold for endothelial cell growth, enhancing healing and reducing post-procedure complications. The proprietary delivery system allows for precise navigation within the brain's blood vessels, and the polymer component dissolves over time, facilitating follow-up imaging procedures. The stents are marketed to hospitals and neurosurgical practices globally, with a focus on North America, Europe, and emerging markets in Asia.

Fluid Biomed generates revenue through direct sales of its brain stents to hospitals and specialized medical facilities. Operating on a B2B model, the company sells its advanced medical devices to healthcare providers for surgical procedures aimed at brain aneurysms. The pricing aligns with industry standards for high-tech medical devices, reflecting the unique benefits of their hybrid polymer-metal design. The company's flagship product, the polymer-based flow-diverting stent, is targeted as a premium offering, emphasizing patient safety and treatment effectiveness, with strategic partnerships to enhance market accessibility.

In December 2024, Fluid Biomed secured CAD 38. 42 million in Series A funding, co-led by Amplitude, to support the development of its polymer-based stent technology. The company plans to expand its product line and is focusing on entering new geographic markets, particularly in Asia, by 2025. The recent funding will facilitate these initiatives, enabling the launch of new products and enhancing operational capacity to meet growing demand.